A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether use of aprotinin in coronary artery bypass graft surgery adversely affects graft patency. Altogether 45 papers were identified using the below mentioned search, of which 10 presented the best evidence to answer the clinical question. The author, journal, date and country of publication, patient group studied, study type, relevant outcomes, results, and study weaknesses of these papers are tabulated. We conclude that aprotinin clearly reduces blood loss, requirement for blood transfusion, and the risk of reoperation for bleeding, but does increase the risk of saphenous vein graft occlusion
AbstractBackgroundTotal arterial grafting is increasingly preferred in coronary artery bypass grafti...
Background. Aprotinin, a non-specific serine protease inhibitor, has been used for two decades to re...
BACKGROUND Aprotinin has been used to reduce blood loss and blood product transfusions in patients a...
OBJECTIVE: Despite proven blood transfusion benefits, aprotinin may be underused in coronary artery ...
To assess the thrombotic risk of aprotinin in aortocoronary bypass surgery, we retrospectively analy...
To assess the thrombotic risk of aprotinin in aortocoronary bypass surgery, we retrospectively analy...
PURPOSE: Medical decisions are often made based on personal experience or on limited clinical trial ...
AbstractObjectiveDespite proven blood transfusion benefits, aprotinin may be underused in coronary a...
Study Objectives. To determine if aprotinin is safe and effective in patients at low risk for requir...
The aim of our study was to compare a systemic and a local aprotinin application in patients during ...
AbstractObjective: We examined the effects of aprotinin on graft patency, prevalence of myocardial i...
To assess the impact of systematic use of aprotinin, 115 consecutive adults undergoing cardiac surge...
BACKGROUND: There is still uncertainty about the safety of aprotinin for coronary artery bypass graf...
Background: There is still uncertainty about the safety of aprotinin for coronary artery bypass graf...
A best evidence topic in cardiac surgery was written according to a structured protocol. The questio...
AbstractBackgroundTotal arterial grafting is increasingly preferred in coronary artery bypass grafti...
Background. Aprotinin, a non-specific serine protease inhibitor, has been used for two decades to re...
BACKGROUND Aprotinin has been used to reduce blood loss and blood product transfusions in patients a...
OBJECTIVE: Despite proven blood transfusion benefits, aprotinin may be underused in coronary artery ...
To assess the thrombotic risk of aprotinin in aortocoronary bypass surgery, we retrospectively analy...
To assess the thrombotic risk of aprotinin in aortocoronary bypass surgery, we retrospectively analy...
PURPOSE: Medical decisions are often made based on personal experience or on limited clinical trial ...
AbstractObjectiveDespite proven blood transfusion benefits, aprotinin may be underused in coronary a...
Study Objectives. To determine if aprotinin is safe and effective in patients at low risk for requir...
The aim of our study was to compare a systemic and a local aprotinin application in patients during ...
AbstractObjective: We examined the effects of aprotinin on graft patency, prevalence of myocardial i...
To assess the impact of systematic use of aprotinin, 115 consecutive adults undergoing cardiac surge...
BACKGROUND: There is still uncertainty about the safety of aprotinin for coronary artery bypass graf...
Background: There is still uncertainty about the safety of aprotinin for coronary artery bypass graf...
A best evidence topic in cardiac surgery was written according to a structured protocol. The questio...
AbstractBackgroundTotal arterial grafting is increasingly preferred in coronary artery bypass grafti...
Background. Aprotinin, a non-specific serine protease inhibitor, has been used for two decades to re...
BACKGROUND Aprotinin has been used to reduce blood loss and blood product transfusions in patients a...